araag2/HINT huggingface dataset:
Clinical trial NCT02958163 (phase 2, status: terminated)
Conditions: liver neoplasms, hepatocellular cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, P59.20, P59.29
Drugs: doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatocellular carcinoma larger than 3 cm and non-resectable, with a diagnosis
             established either by:

               -  dynamic imaging (non-invasively), showing a typical contrast enhancement and
                  wash-out

               -  histopathology

          -  satellite lesions are allowed (at most three lesions) as long as the doses constraints
             are still achievable

          -  Hepatocellular carcinoma belonging to Barcelona Clinic Liver Cancer Stage System class
             B

          -  Tumor must be measurable on a multi-phase MRI according to mRECIST criteria

          -  Non-tumoral liver volume ≥ 800 cc

          -  Child-Pugh (CP) A to B7 cirrhosis

          -  HCC Patients can be included if they require treatment prior to liver transplantation

          -  ECOG performance status 0-1

          -  AST/ALT < 5 times ULN

          -  Initial platelets ≥ 50 000 x 10E9/l, neutrophils > 1500 x 10E9/l, Hb > 9 g/dl

          -  Serum creatinine < 1.5 X normal, or calculated Creatinine clearance rate ≥ 60 mL/min

          -  As tumor biopsy can be performed after inclusion, pure hepatocellular carcinoma but
             also mixed hepatocellular carcinoma will be allowed in this trial. Cholangiocarcinoma
             cannot be included.

          -  Written informed consent form to be signed,

          -  Patient willing and able to comply to the follow-up schedule

          -  Patients in fertile age should use a contraceptive method during treatment and 4
             months after.

        Exclusion Criteria:

          -  Eligibility for resection or ablative treatments

          -  Extra hepatic spread of the disease

          -  Previous treatment of the same lesion with TACE

          -  Previous treatment with selective internal radiotherapy or radiotherapy to the upper
             abdomen

          -  Uncontrolled Ascites

          -  Uncontrolled Encephalopathy

          -  Any clinical sign of acute viral or non-viral hepatitis (new serological testing are
             not required)

          -  Known current pregnancy

          -  Uncontrolled active co-morbidity
Clinical trial NCT02963311 (phase 2, status: completed)
Conditions: homozygous familial hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: aln-pcssc, standard of care
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, ≥12 years of age with a diagnosis of homozygous familial
             hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a
             history of an untreated low-density lipoprotein cholesterol (LDL-C) concentration >500
             mg/deciliter (dL) [13 millimoles/liter (mmol/L)] together with either xanthoma before
             10 years of age or evidence of heterozygous familial hypercholesterolemia in both
             parents.

          -  Stable on a low-fat diet.

          -  Stable on pre-existing, lipid-lowering therapies (such as statins,
             cholesterolabsorption inhibitors, bile-acid sequestrants, or combinations thereof) for
             at least 4 weeks with no planned medication or dose change for the duration of study
             participation.

          -  Fasting central lab LDL-C concentration >130 mg/dL (3.4 mmol/L) and triglyceride
             concentration <400 mg/dL (4.5 mmol/L).

          -  Body weight of 40 kilograms (kg) or greater at screening.

        Exclusion Criteria:

          -  LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to
             receive it during the study because of the attendant difficulty in maintaining stable
             concentrations of LDL-C while receiving apheresis.

          -  Use of mipomersen or lomitapide therapy within 5 months of screening.

          -  Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks of
             screening.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02970968 (phase 2, status: unknown status)
Conditions: gastroparesis
ICD codes: K31.84
Drugs: vly-686 (tradipitant)
SMILES: FC(F)(F)C1=CC(=CC(CN2N=NC(=C2C2=CC=NC=C2)C2=NC=CC=C2C(=O)C2=CC=CC=C2Cl)=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosed with gastroparesis;

          2. Subjects must agree to the use of contraception

          3. Ability and acceptance to provide written informed consent;

          4. Willing to participate in the pharmacogenomics sample collection;

          5. Willing and able to comply with all study requirements and restrictions

          6. Willing to not participate in any other interventional trial for the duration of their
             participation.

        Exclusion Criteria:

          1. Another active disorder or treatment which could explain or contribute to symptoms in
             the opinion of the Investigator (including but not limited to gastric malignancy,
             neurological disorder, or heavy doses of strong anticholinergics);

          2. Pregnancy or nursing;

          3. History of intolerance and/or hypersensitivity to medications similar to VLY-686
             (Tradipitant) and its accompanying excipients;

          4. Use of another NK1 antagonist or palonosetron;

          5. Exposure to any investigational medication, including placebo, within 60 days of the
             Baseline Visit;

          6. Any other reason as determined by the Investigator which may lead to an unfavorable
             risk-benefit of study participation, may interfere with study compliance, or may
             confound study results.
Clinical trial NCT02971228 (phase 2, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin lispro, zp4207 (dasiglucagon), glucagon
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with T1DM for at least 1 year, as defined by the American Diabetes
             Association

          2. Age ≥ 18 years

          3. Prescription medication regimen stable for >1 month (except for medications not
             expected to affect trial safety or outcome, in the judgment of the investigator)

          4. Diabetes managed using an insulin pump for >=6 months

          5. Patients in good health according to age (medical history, physical examination, vital
             signs, 12-lead electrocardiograms [ECGs], laboratory assessments), as judged by the
             Investigator

        Exclusion Criteria:

          1. Previous exposure to ZP4207 or adverse reaction to glucagon

          2. History of liver disease or current abnormal liver function tests (LFTs)

          3. Renal failure

          4. Anemia

          5. History of coronary artery disease or congestive heart failure (class III or IV)

          6. History of transient ischemic attack or stroke

          7. Seizure disorder

          8. Cystic fibrosis, pancreatitis, or any other pancreatic disease besides T1DM

          9. Other endocrine disorders

         10. Use of oral anti-diabetic medications

         11. Electronically powered implants

         12. Hypertension (≥160/100 mm Hg despite treatment)

         13. Inadequate venous (vein) access as determined by trial nurse or physician at time of
             screening
Clinical trial NCT02973100 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dulaglutide, placebo
SMILES: CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have had type 2 diabetes (T2D) for ≥6 months according to the World Health
             Organization (WHO) classification

          -  Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory

          -  Have been treated with stable doses of metformin for at least 3 months

          -  Have a body mass index (BMI) ≥25 kilograms per square meter

        Exclusion Criteria:

          -  Have type 1 diabetes (T1D)

          -  Have used any glucose-lowering medication other than metformin 3 months prior to study
             entry or during screening/lead-in period or have used any glucagon-like peptide-1
             receptor agonists (GLP-1 RAs) at any time in the past

          -  Have had any of the following cardiovascular conditions: acute myocardial infarction
             (MI), New York Heart Association Class III or Class IV heart failure, or
             cerebrovascular accident (stroke)

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
             than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level
             >2.5 times the upper limit of the reference range, as determined by the central
             laboratory at study entry; participants with NAFLD are eligible for participation in
             this trial

          -  Have had chronic or acute pancreatitis any time prior to study entry

          -  Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 square
             meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation

          -  Have serum calcitonin ≥20 picograms per milliliter, as determined by the central
             laboratory at study entry
Clinical trial NCT02975206 (phase 2, status: completed)
Conditions: pruritus, atopic dermatitis
ICD codes: L29.0, L29.1, L29.2, L29.8, L29.9, L29.3, L20.89, L20.9
Drugs: serlopitant high dose, placebo oral tablet, serlopitant low dose
SMILES: C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl, C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age 13 years or older

          -  Pruritus prior to and during the initial screening period

          -  Diagnosis of atopic dermatitis

          -  Judged to be in good health in the investigator's opinion

        Exclusion Criteria:

          -  Prior treatment with study drug or similar drug

          -  Pruritus due to another reason besides atopic dermatitis

          -  Presence of any medical condition or disability that could interfere with study

          -  History of hypersensitivity to serlopitant or any of its components

          -  Currently pregnant or male partner of pregnant female

          -  Females of childbearing potential who are unable or unwilling to use adequate
             contraception or who are breast feeding
Clinical trial NCT02976467 (phase 2, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: fulacimstat (bay1142524), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with first ST elevation myocardial infarction (STEMI) treated with primary
             percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset

          -  Diagnosis of STEMI requires the presence of the following three criteria:

               -  Typical clinical symptoms such as chest pain, shortness of breath for more than
                  20 minutes related to the myocardial infarction

               -  New ST elevation indicating myocardial infarction

               -  Significant elevation in troponin T or I with at least one value above the 99th
                  percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and
                  creatine kinase MB (6-10% of total CK)

          -  At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45%
             and an infarct size >10% LV mass (as measured by LGE-MRI, central-blinded evaluation)

        Exclusion Criteria:

          -  Contraindication to perform contrast-enhanced cardiac MRI

          -  LVEF < 20%

          -  History of heart failure or LVEF < 50% before occurrence of the first STEMI

          -  Infarct size > 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction

          -  NYHA (New York Heart Association) class IV at randomization

          -  Any planned cardiac intervention after baseline MRI or any other planned operations

          -  Non-ischemic causes for cardiomyopathy

          -  Diagnosis of atrial fibrillation

          -  Systolic blood pressure < 100 mm Hg or > 180 mm Hg; diastolic blood pressure < 50 mm
             Hg or >110 mm Hg, heart rate < 50 or >100 beat/minute; mean of triplicate values at
             randomization

          -  Clinically relevant hepatic dysfunction
Clinical trial NCT02978781 (phase 2, status: completed)
Conditions: essential tremor
ICD codes: G25.0
Drugs: sage-217, sage-217, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participant must have a diagnosis of Essential Tremor (ET), defined as bilateral
             postural tremor and kinetic tremor, involving hands and forearms, that is visible and
             persistent and the duration is >5 years prior to screening.

        Key Exclusion Criteria:

          -  Participant has presence of abnormal neurological signs other than tremor or Froment's
             sign.

          -  Participant has presence of known causes of enhanced physiological tremor.

          -  Participant has concurrent or recent exposure (14 days prior to admission visit) to
             tremorogenic drugs.

          -  Participant has had direct or indirect trauma to the nervous system within 3 months
             before the onset of tremor.

          -  Participant has historical or clinical evidence of tremor with psychogenic origin.

          -  Participant has convincing evidence of sudden tremor onset or evidence of stepwise
             deterioration of tremor.
Clinical trial NCT02981498 (phase 2, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: folfox protocol
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Criteria:

        Inclusion Criteria:

          -  The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
             Association for the Study of the Liver (EASL)

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria.

          -  diagnosed with major or main portal vein invasion (Vp3 or Vp4)

          -  KPS≥70；

          -  with no previous treatment

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  The following laboratory parameters:

               -  Platelet count ≥ 75,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 30mmol/L

               -  Serum albumin ≥ 30 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) >1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease
Clinical trial NCT02984995 (phase 2, status: completed)
Conditions: leukemia, myeloid, acute
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: quizartinib
SMILES: CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
Eligibility criteria:

        Inclusion Criteria:

          -  AML patients in first relapse or refractory after all prior therapy

          -  Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  AML secondary to prior chemotherapy for other neoplasms.

          -  Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML
             therapy

          -  Prior treatment with a FLT3 targeted therapy

          -  Active infection not well controlled by antibacterial, antifungal and/or antiviral
             therapy
Clinical trial NCT02985879 (phase 2, status: terminated)
Conditions: progressive supranuclear palsy
ICD codes: G23.1
Drugs: placebo, abbv-8e12
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was prematurely discontinued because the program for progressive supranuclear palsy
    was discontinued due to lack of efficacy of study drug.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female participant with age 40 years or greater at the time of signed consent

          -  Meets the criteria for possible or probable progressive supranuclear palsy (PSP;
             Steele-Richardson-Olszewski Syndrome)

          -  Presence of PSP symptoms for less than 5 years

          -  Participant is able to walk 5 steps with minimal assistance (stabilization of one arm
             or use of cane/walker)

          -  Participant has an identified, reliable, study partner (e.g., caregiver, family
             member, social worker, or friend)

        Key Exclusion Criteria:

          -  Participants who weigh less than 44 kg (97 lbs) at screening

          -  Mini-Mental State Examination (MMSE) score less than 15 at screening

          -  Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)

          -  Participant resides at a skilled nursing or dementia care facility, or admission to
             such a facility is planned during the study period

          -  Evidence of any clinically significant neurological disorder other than PSP

          -  The participant has a history of or currently has schizophrenia, schizoaffective
             disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental
             Disorders, 5th Edition (DSM-V) or International Classification of Diseases (ICD-10)
             criteria

          -  Participant has had a significant illness or infection requiring medical intervention
             in the past 30 days
Clinical trial NCT02992288 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), neladenoson bialanate (bay1067197), placebo
SMILES: C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women aged 18 years and older

          -  Diagnosis of chronic heart failure (CHF), NYHA ( New York Heart Association ) class
             II-IV, LVEF ≤ 35% and elevated NT-proBNP

        Exclusion Criteria:

          -  Acute de-novo heart failure

          -  Requirement of any intravenous (IV) treatments following 48 hours prior to
             randomization

          -  Mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation,
             mechanical ventilation, or any ventricular assist device)

          -  Any cause of chronic heart failure other than ischemic cardiomyopathy and idiopathic
             dilated cardiomyopathy
Clinical trial NCT03000075 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: risankizumab, placebo for risankizumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for
             at least 6 months before the first administration of study drug. Duration of diagnosis
             may be reported by the patient.

          -  Have stable moderate to severe chronic plaque psoriasis with or without psoriatic
             arthritis at both Screening and Baseline (Randomisation):

               1. Have an involved body surface area (BSA) ≥10% and

               2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and

               3. Have a Static Physician Global Assessment (sPGA) score of ≥3.

        Exclusion Criteria:

          -  Patients with

               1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)

               2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta
                  blockers, calcium channel blockers, or lithium)

               3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis
                  that might confound trial evaluations according to investigator's judgment

          -  Previous exposure to BI 655066